미국 · 보도자료 · COYA · 2026-10-05 12:00
루게릭병 치료제 COYA 302 임상 2/3상 환자 등록 완료
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced full enrollment of the planned 120 participants in the Company’s Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302, Coya’s combination
